Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections

IMPORTANCE: Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease. The associations of these 2 oral antiviral drugs with hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Dan-Yu, Abi Fadel, Francois, Huang, Shuaiqi, Milinovich, Alex T., Sacha, Gretchen L., Bartley, Patricia, Duggal, Abhijit, Wang, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514733/
https://www.ncbi.nlm.nih.gov/pubmed/37733342
http://dx.doi.org/10.1001/jamanetworkopen.2023.35077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514733/
https://www.ncbi.nlm.nih.gov/pubmed/37733342
http://dx.doi.org/10.1001/jamanetworkopen.2023.35077

Ejemplares similares